Cipla Limited Phytonadione Injectable Emulsion, USP 10mg/mL recall: Failed Stability Specifications: Observed OOS results: eg results for colour
Failed Stability Specifications: Observed OOS results: eg results for colour index
The hazard: Potency, impurity or stability failure
This is a specification failure: testing showed the product does not match what the label promises.
What the notice says: Failed Stability Specifications: Observed OOS results: eg results for colour index
Why it matters: The product failed a specification test: it may contain more or less active ingredient than the label states, carry an impurity, or degrade before its expiry date. A sub-potent dose can leave a condition untreated; a super-potent one can cause an overdose.
Symptoms and when to call a doctor
The risk depends entirely on the drug. For a medicine where dose matters closely — a blood thinner, an anti-epileptic, a thyroid or heart medicine, insulin — talk to your prescriber before changing anything. Seek urgent care if you have symptoms that suggest too much drug, or if the condition the medicine controls starts breaking through.
This page is general information, not medical advice. If you feel unwell, a clinician who can see you is the only person able to judge your case.
Recall details
- Recall number
- D-0197-2026
- Published
- December 10, 2025
- Risk level
- Class II
- Status
- Ongoing
- Issued by
- U.S. Food and Drug Administration
- Brand
- Cipla Limited
- Product type
- Prescription & OTC drugs
- Units affected
- 4,438 10x1mL cartons
- Distribution
- Nationwide
- Made in
- India
- Lot / code info
- Batch # PH0072404A, PH0082404A, Exp. Date December 31, 2025
Products covered by this recall
Phytonadione Injectable Emulsion, USP 10mg/mL, 10x1 mL Single-Dose Vial/carton, Rx Only, Mfd. by: Cipla Ltd. India At M/s Immacule Lifesciences PVT. Ltd. India. Mfd. for: Cipla USA, Inc. Warren, NJ 07059. Vial NDC# 69097-708-31; Carton NDC 69097-708-96
Check your product
The notice names 11 codes you can read straight off the package. Type the one printed on yours and the list below narrows to it.
Lot or batch code
Usually ink-stamped near the seam, the cap or the bottom of the pack.
- PH0072404A
- PH0082404A
- 2025 — 4
- 438 10x1mL cart
Best-by / use-by date
Printed beside the lot code, not on the price sticker.
- December 31
- 2025 — 4
- 438 10x1mL cartons
NDC number
On the carton and again on the bottle or blister label.
- 69097-708-31
- 69097-708-96
Package size
Match the net weight or the piece count on the front of the pack.
- 10 mg
- 1 mL
Codes are lifted verbatim from the FDA — Drug enforcement notice. A code that is missing here may still be covered — the official notice is the complete list.
What to do about Potency
Cipla Limited — This is a specification failure: testing showed the product does not match what the label promises.
- Check the lot number on your pack against the codes listed above before you do anything else.
- Keep the carton and the leaflet — the lot number is usually printed only on the outer pack.
- Report any change in how the medicine is working to FDA MedWatch, which is where most of these signals originate.
- Do not stop a prescription on your own. For most conditions an uncertain dose is safer than no dose while you get advice.
Refunds and replacements
With medicines, a replacement supply matters more than cash, and that is what pharmacies are set up to provide.
- Ask the dispensing pharmacy for a like-for-like replacement from an unaffected lot. This is the fastest route and usually costs nothing.
- For a mail-order or online pharmacy, use the recall line listed on this page rather than the general support queue.
- If the recall voided a fill you had already paid for, your insurer will normally authorise a replacement ahead of schedule. Quote the recall number.
- If you paid out of pocket, ask for a refund of the co-pay or purchase price and keep the receipt the pharmacy issues.
Company contact: Cipla Limited — Plot No. 9 & 10, Pharma Zone Phase Ii, Pithampur, District Dhar
The official notice
This page summarises a notice published by U.S. Food and Drug Administration. The agency notice is the authoritative version — read it before you act, and treat it as the final word if anything here looks different.
Open the FDA — Drug enforcement record U.S. Food and Drug Administration recalls
Questions people ask about this recall
Why was Cipla Limited prescription & otc drugs recalled?
Failed Stability Specifications: Observed OOS results: eg results for colour index Failed Stability Specifications: Observed OOS results: eg results for colour index
How do I know if I have the recalled product?
Match the codes printed on your package against the notice: lot code PH0072404A, PH0082404A, 2025 — 4; best-by date December 31 or 2025 — 4. If the code on your package is not on that list, your unit is outside the recall.
What should I do with it right now?
Check the lot number on your pack against the codes listed above before you do anything else.
Can I get my money back?
Ask the dispensing pharmacy for a like-for-like replacement from an unaffected lot. This is the fastest route and usually costs nothing.
Where was the recalled product sold?
It was distributed nationwide.
Related recalls
-
Class II · 11 days ago
Cipla USA, Inc. Fosfomycin Tromethamine Granules for Oral Solution recall: Failed Impurities/Degradation Specifications
Failed Impurities/Degradation Specifications
-
Class II · 4 months ago
Cipla USA, Inc. Cinacalcet Hydrochloride Tablets, 30 mg, 30-count bottle recall: cGMP Deviations: presence of N-nitroso-cinacalcet
cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).
-
Class II · 4 months ago
Cipla USA, Inc. Cinacalcet Hydrochloride Tablets, 90 mg, 30-count bottle recall: cGMP Deviations: presence of N-nitroso-cinacalcet
cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).
-
Class II · 4 months ago
Cipla USA, Inc. Cinacalcet Hydrochloride Tablets, 60 mg, 30-count bottle recall: cGMP Deviations: presence of N-nitroso-cinacalcet
cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).
-
Class II · 6 months ago
Cipla USA, Inc. Cinacalcet Hydrochloride Tablets, 30 mg, 30 Tablets per bottle recall: CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily
CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit
-
Class II · 6 months ago
Cipla USA, Inc. Cinacalcet Hydrochloride Tablets, 90 mg, 30 Tablets per bottle recall: CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily
CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit